Senti Biosciences is trading 6.95% up at $0.46, with no clearly reported company-specific overnight catalyst identified for August 19, 2026.
- Investor attention may be increasing ahead of the scheduled Q2 2026 earnings discussion on August 20, although timing does not establish causation.
- The latest reported quarter showed a $12.75 million net loss, down from $14.73 million a year earlier.